摘要
目的:探究酒石酸美托洛尔对心脏瓣膜病伴心力衰竭患者的影响。方法:选取2013年3月-2016年3月本院收治的118例心脏瓣膜病伴心力衰竭作为研究对象,以随机双盲法将患者分为观察组(59例)与对照组(59例),对照组予以常规药物治疗,观察组在对照组治疗基础上联合酒石酸美托洛尔治疗,对比两组治疗后疗效、药物不良反应,治疗前后患者心功能各项指标、心率、血清脑钠肽(BNP),并采取明尼苏达州心力衰竭生活质量问卷(ML-WHF)评估患者6个月后生活质量。结果:观察组总有效率为96.61%,显著高于对照组的84.75%(P<0.05);观察组治疗前心功能各项指标及BNP均相当(P>0.05),治疗后观察组心功能各项指标及BNP水平、心率均优于对照组(P<0.05);观察组患者治疗半年后ML-WHF问卷评分显著优于对照组(P<0.05);观察组药物不良反应发生率为1.69%,与对照组相当(P>0.05)。结论:酒石酸美托洛尔治疗心脏瓣膜病伴心力衰竭具有良好效果,且药物不良反应反应少,患者心功能明显改善,生活质量提升,具有较高临床应用前景。
Objective：To explore the impact of Tartaric Acid Metoprolol in valvular heart disease and heart failure.Method：From March 2013 to March 2016,118 cases of heart valve disease and heart failure were selected as the research objects,with random double blind method they were divided into the observation group（n=59） and the control group（n=59）.The control group was given routine drug treatment,the observation group on basis of the control group was given Tartaric Acid Metoprolol therapy.Thecurative effect,adverse drug reaction after treatment,the indicators in patients with cardiac function before and after the treatment,heart rate,serum brain natriuretic peptide（BNP）,and Minnesota heart failure patients with quality of life questionnaire（ML-WHF） evaluation quality of life after 6 months of two groups were compared.Result：The total effective rate of the observation group was 96.61%,was significantly higher than 84.75% of the control group（P〈0.05）.Before treatment,the indexes of cardiac function and BNP level of two groups were quite（P〉0.05）,after treatment the indexes of cardiac function,BNP level and heart rate of the observation group were superior to those of the control group（P〈0.05）.After six months ML-WHF questionnaire score of the observation group was significantly better than that of the control group（P〈0.05）.The drug adverse reaction rate of the observation group was 1.69%,and the control group was 0（P〉0.05）.Conclusion：Tartaric Acid Metoprolol treatment of valvular heart disease with heart failure has good effect,and less drug adverse reactions,patients with cardiac function improved significantly,the quality of living,has a high clinical application prospect.
出处
《中国医学创新》
CAS
2017年第2期5-8,共4页
Medical Innovation of China
基金
辽宁省博士科研启动基金计划拟资助项目(20141099)
关键词
心脏瓣膜病
心力衰竭
酒石酸美托洛尔
心功能
血清脑钠肽
Valvular heart disease
Heart failure
Tartaric Acid Metoprolol
Cardiac function
Serum brain natriuretic peptide
